replay and welcome here And is Thank for following and you webcast is available. Thank accompanying an on to our us – a ir.navidea.com, website, today on remarks, call be earnings joining made live There we you. prepared our everybody. will call. being This Mr. and its live Vice Chair, its are a conducting Chair Vice be on here Cappello; of Session. Navidea's the Eves; of today. Kim Alex Scott; Administration, its joining you will Q&A Board me President Finance of Erika Directors, call Mr.
of conference data These molecular readouts, and immunotherapeutics, and which future course performance the clinical plans relate will regulatory During the strategic resources matters. regarding diagnostics and developments company. the business this Navidea's events be statements making develop clinical forward-looking of of and along include to we timing events capital and future with our call, to
events recent risks quarterly Investors website and annual today. the management assume could most statements, involve or results a statements to uncertainties information, as read beliefs with and carefully as should differ the SEC. of the cause the these well are as update or revise assumptions, result new Harbor section of obligation in and included and company's the whether certain future within described our We uncertainties materially. otherwise. Safe of risk as on of to All the based risks expectations These factors filings no actual and forward-looking of statements
in is be will the trial Company FDA NDA this in management fully full of our planning. few of goal success trial XXXX. thought Three, detail mission focus of potential with RA of areas fund we’ll Phase engaged multiple and it trial. Directors key to retain capital approval. enrollment, begin would funding, continue I X X we fully be identify full talent. a As Board XXXX and the RA we in One, biopharmaceutical are we’ll support our attract and submission providers Two, to our our Phase our update, to the to funded top helpful
development support team achievements, our strategic RA as new share milestone success PR/IR does success. support grow help relationships, to our program a the grows, way our key and to milestone key need trial As initiate so efforts and to
loan $X.X proceeds most at specifically, arm with successfully up same an proceeds offering. in through its the QX look company's from additional If raised bridge company million capacity the place from Directors, recent of exercised, Group. Mr. in banking Maxim warrant may its we million received The additional of be Chair in rights received Vice As company $XX.X bridge also $X offering Board the successfully facility the using Scott. the million currently same exercise of to rights that of investment of
received from payment reimbursement also development of certain partner. $XXX,XXX accelerated for and an a We strategic research expenses
other in rheumatoid We have indications therapeutic. in trials clinical arthritis diagnostic as advanced well our in pipeline and as our
support RA, or on fibroid hypotheses expression the a the continue to CDXXX Xb of international as this data by from presented the early strong trial evaluated participants RA. moment. do in ability presentation in results biopsy first excellent week on joints We of of non-fibroid These supporting and time pathotype promising our a patients imaging results provide up in the tilmanocept the finalization. at our More solid distinguish arthritis our rheumatoid imaging of with comparing that make Phase progress preliminary to to the tilmanocept’s in and in support conference biomarker
August September, in open open additional to into sites enroll bringing to our Phase We XX. and the up also X total and early continue
the across collaborations existing therapeutics to property. advance advance and continue work intellectual globe grow as to and with we imaging applications key also through well-known our the investigators We and institutions company's
very the the to benefit are in we we shareholders planning our place of associates Navidea. putting We made proud here and have at progress are and our
matters, essentially the company company had Goldberg bracket the two has in Regarding to rulings both, that exposure the CRG its will exposure. Dr. minimize and litigation continue
I a update results. begin Now program. specific clinical our the I to provide our would will like to with arthritis in progress brief rheumatoid
trial, we're FDA up our to So we mentioned those enroll approval The we've opened announced nine continue indications RA. in just additional into that pursuing X Phase for as recently We've sites. I initial are respond low early who therapy. treatment prediction first-time therapy. two, to response of likely RA new of one, anti-TNFα levels anti-TNFα with to to a or are: identify patients less localization And to
working, is can for drug high costs not along side the this and that treated health patient's to with discussed there of because working bring not a RA unmet long-term is have whether disease possible them with in a being we unnecessary reliable if with previously, need effects. predictor lead consequences therapy is patient therapies drug a a for large is As early ineffective
Our ability of Phase will recruitment. trial of tilmanocept patients predictor that to imaging to an tilmanocept anti-TNFα our response RA as an biopsy, early addressing therapy medical serve study comparison X remains unmet an joint the imaging NAVX-XX, switching of active to in establish treatment need.
trial are As preliminary announced discussed of and previously, promising. we've results the this
enroll subtypes trial comparative types of that and is three RA results. And patho fibroid, myeloid is each the so minimum imaging and each four aim of of recruit the to Our RA, lympho-myeloid. to obtain the subjects diffuse of a in we designed of patients three with pathology
predict more of of three has the both size pathobiology the and XX their of tissue. to more range pathotype and objective relationship So values individual study trial biopsies imaging XX joint-specific growing not of of There's or suggesting overall literature which whether as participants. joint between and may number enrolled those buckets have with because or patients rheumatology. The primary this patient in out clinically had means those of is fibroid RA and are leaders key much Knowledge patient's drugs, that RA of expected to two we less achieve type uptake extremely it To-date, therapy with particular participants assess likely anti-TNF-alpha of respond. is important in so of been opinion having patient joint minimum a to RA completed. seen this involved patients tilmanocept body determining a between responsive the RA pathotype to a and important is an the XX to a has be to of pathotype may the a
This Rheumatology pathotypes the hypothesized is reliable do is of low a able with to discreetly We no conference this diffuse this of of time, patients patients patient's biopsy doing RA. largest of indicated the a College having way the results those RA in is i.e., other pathotype invasive information have These macrophage at i.e., from XX fibroid American assessing updated by of tilmanocept myeloid in could virtual the those results finished than to the showing with an rheumatology As there RA of provide world. this we just a that with tilmanocept patient's differentiate involvement a week's or that involvement. inflamed providing joints and on biopsy, preliminary lympho-myeloid Meeting. by higher pathtype RA either way uptake those macrophage first
has our data today, or one ability Phase taken based as we've in time indications provides either able imaging of in results from from our fibroid that a significant that non-fibroid a X classify is on also patient receive participants. been fibroid clinical the benefit if increasing biopsy benefit mentioned, support baseline As all patient Since, they're an trial, likely of meaningful to predict for from anti-TNF-alphas. type likely to I scan before alone a the as evidence These this a clearly patients XX receive to therapy. whether is anti-TNF-alpha RA, less of there to
level we at at our NAV early response. the efficacy their XXX, clinical an joints anti-TNF-alpha on previously using that Xb gold tilmanocept almost of in their trial scan uptake assessment. of Those where who You patients recall non-response prediction looked alone XX% rate therapy imaging of Phase might a baseline in standard the exhibited had in treatment to study, completed tilmanocept low
these with of well, early in these is the with have with imaging promising companies additional discussions we as in the differentiator trial possibility hold discussions results continue hand forward promising work, good we with biomarker key even product. for commercial have being for benefit The we up automating move to as prior these pipeline. for have Importantly, RA if had developing and results will significant progress drug to completion, used companies current which a data we development between image very pharmaceutical be and conversations quantification in will opened which position to in that better an as make tilmanocept have therapeutics now the
sensitive full the in a imaging but adoption large is is mind commercial the using of quantitative This earlier significant medical intent the in use medicine of accurate reproducably deriving image for critical We database and large software software of also application work agreement proprietary from develop only to images, using scale before, can space. a image have be and work competitors that robustly normative in critical pilot possible you've trials perform data they tilmanocept it nuclear images to continue RA. our demonstrating to read entry fully analysis product. our commercial closely this our company the with study as reproduce serves them and built, to discussed a at and imaging space. that that all which rollout well a They again, will upon of with for – widespread our leading as Once the automated of completed to partner the means of letter to RA. imaging the of The MIM is methodology automated footprint can MIM RA to tilmanocept a on quantitative data our not intent of readouts rapidly letter barrier and including a it be algorithm. important in most as for is Keep for ability quantification continue reads our and through this, to
and to are Boston localization in The that to support. The of when to Hospital atherosclerotic of of investigator-initiated of plaque line pipeline terms and group University collaborations significantly General at published and development make Birmingham sites was in released continue an what diagnostics We publication to recent it results co-published the the we We study Preclinical them will at in on study plaque Alabama the can tilmanocept studies with the UAB. imaging through researchers reference find related promised help announcement PET of in or Massachusetts we internal you other next-generation this agents of through atherosclerotic the areas Manocept so in will Gallium most MIM here and data cardiovascular release. the of and finalize publication our reported we're work at with our for previously. press imaging tilmanocept imaging terms to that partnership disease. Navidea have XX extramural with progressed at in work with completed pilot in
imaging tilmanocept-like on work with XX tilmanocept was looked We in our when set which important is showing our to preclinical to has at agent is important atherosclerosis. off-target implications imaging localization Nuclear tumors studies blocking work NIH that UAB can successful significantly the currently additional technology by summer. while the and while of the was localization a tissues, various and completed have injection. a Imaging a and intravenous meeting for presented well. funded localization of tilmanocept new target Molecular tilmanocept similar new of to increase imaging agent another evaluating in for Medicine to liver, a dramatically and our highly localization manuscript Gallium block These method liver. imaging of to is preclinical the studies administered the of of major simultaneously imaging of model This site agents, to to second last round studies we mouse on as This agent increase at A were localization therapeutics designed completed off-target Society Work peer-review.
new the to goal inflection and payloads with human spaces asset beneficially doxorubicin drug example. new carry significantly drug, preclinical front, significant constructs INDs investigational points in of These On of Results in drug These demonstrated of or than tumor that altering mice payloads cancer or advancing for combination of are average work new have opportunities with partnering studies delivery drug anti-inflammatory and deals, for has administered XX%. and studies these oncology will be the the tumor may on in alone status in to the reduced be and in filings XXXX. new we applications filing rate the constructs growth therapeutic targeted licensing advance when effective new our constructs progressed. for candidates by macrophages an more immune that therapeutic another
in be can chronic where costs CDXXX-positive constructs advancing fly well macrophage potentially caused SITC change, potentially rare lead by altering bite parasite well FDA for tropics, the was phenotype examining the soon and at Summit we that priority our in of neglected payload constructs new results had spectrum as it and well also SITC the presented candidate that Mass. tested the stream the positive Leishmaniasis work we meeting. is for in serious Leishmaniasis I in protozoan preclinical vectors potentially are ongoing our studies to about tropical making oncology therapeutics the a is sell Southern Some the recently both for tropical than review recently Tumor eligible results pipeline of is or will Society November sand It on novel to tell of shown humans indications. Therapies more is disease voucher back infected a Preclinical at accelerate of indications presented work a Its in of have number through for in bisphosphonate sand the replicates but designated more the paclitaxel More ability Meeting presented other Cancer constructs of fact, subtropics full held XX and are new countries Myeloid-Directed in This covering drugs U.S., the macrophage Leishmaniasis. for models. inflammatory received at for flies vitro of attention. demonstrating a vector-borne Europe. the Immunotherapy parts In for as found found, candidates. of disease. were a development to phenotype our a common, dexamethasone transmitted is enough could Annual as these results life-threatening studies bisphosphonate in disease, has you a Boston, case, steady and were of of in cover The macrophages. as our constructs
macrophages We studies growth further showing have world If And now expressing of The a constructs hold, results for the have these promising in published the of safety model in NIH. in exciting the preclinical indicate vivo of disease, we perform in play at recently leaders studies studies studies. status action NIH. from that XXXX reduce and earlier will of renewed recently a of CDXXX well. collaborators stage disease. dramatically we just company’s form Leishmaniasis last preclinical could mechanism dominant role we in the toxicity studies a replicated constructs of these with These work IND to as our towards advance continue high one the application therapeutic that demonstrating one results we preclinical was at Leishmania several the of the in new parasites mouse these for preclinical therapeutic and with and set the
overall USPTO receive application, Israel notification intellectual the as Manocept-based Leishmaniasis. issuance for me from patent so our the to of And as forward. therapeutic front. of state is well property patent of and moving for the pipeline our brings robust That therapeutic our covering We
our We work applications continue to provisional and pending ones. submit new on
effects and ago. We patent These indications. few in the for have Manocept and linker just two novel in constructs. degradable to being year. a well our studies therapeutic have of and provide have for a and filed was to and for we protection end active indications. describing therapeutic told, This rights new since disease moments payloads application needed on current of our patent inflammatory animal excellent used In next preclinically protections mentioned five company strategy of and we as paclitaxel the the new are with linker diagnostic IP both I that containing an agents patents partnership evaluated provisional oncology some models therapeutic generation dexamethasone will constructs as the our All last filed provisional macrophages attorneys, molecules
active strategy strategy in has distribution marketing of rest right candidates other world, on have supply and the and readiness with countries. commercial and supplier for and towards partnering continued reason The partners find or for our supplier. reliable and product beyond. RA for implications and pharmaceutical and as as as Europe and both we long-term focusing that been API China able of and work of to Europe a Lymphoseek be manufacturing and to work ingredient company for as for for Lymphoseek supply. remains final in is of well and supply partners the Lymphoseek Lymphoaim new marketing in to our product need Regarding this these drug and distribution. the in continues time, and been these the pipeline of to This Lymphoseek a advancing stream completion On we a has and this we front drug for are we to clinical steady Progress a India product, are
by release study are seen press this forward. You in Australia colleagues publication and going have was such investigator our coming first of enthusiastic a might and of an Lymphoseek out investigator using this announcing the tilmanocept, using Australian manuscript Australia about his
and these the trial as and of We the for as the So biopsy largely update. just of push highlights to on Phase touch continue therapeutic our X on the X, diagnostic well the specifically while that wanted indications. imaging this some last are we pipeline, to for Phase quarter RA on focused remain progress to I support other
trial of keep team things work. I to to moving, and their collaborators hard always, clinical network research the our thank sites academic all of here their for As want tireless efforts for
financial it turn pipeline to to inflection appropriate With commercialization Our for for seek and that, remains partnerships Erika? our marketing. over advance to key now points updates. strategy products Erika I’ll and
